Dostarlimab

Global Healthcare Executive Jill DeSimone Joins Swim Across America Board of Directors

Retrieved on: 
Thursday, February 15, 2024
UCSF, Hospital, Teva Pharmaceuticals, Survivor, Merck, Swim Across America, Multimedia, Education, SAA, Dostarlimab, Immunotherapy, FDA, Teva, Friends, Nantucket Cottage Hospital, Growth, Weill Cornell Medicine, Volunteering, Bristol Myers Squibb, Commercial, Sound, Merck & Co., Johns Hopkins University, Health, Patient, Clinical trial, Seattle Cancer Care Alliance, GSK plc, Olympian, Research, Cancer, Pharmaceutical industry

CHARLOTTE, N.C., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Swim Across America, a national nonprofit dedicated to providing grants for cancer research and patient programs and raising funds through swimming events, is pleased to announce that Jill DeSimone, a global pharmaceutical executive, has been appointed to the Swim Across America Board of Directors. Jill's career included championing excellence in patient care for serious diseases, while igniting scalable growth and agility in the healthcare marketplace. She held positions of executive leadership for more than 30 years, culminating in eight years as president of Oncology for Merck.

Key Points: 
  • After a Successful Career with Oncology Pharmaceutical Companies, Jill DeSimone is Making Waves in the Fight Against Cancer
    CHARLOTTE, N.C., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Swim Across America , a national nonprofit dedicated to providing grants for cancer research and patient programs and raising funds through swimming events, is pleased to announce that Jill DeSimone, a global pharmaceutical executive, has been appointed to the Swim Across America Board of Directors.
  • "One of my greatest joys has been volunteering and encouraging many of my colleagues and friends to volunteer with Swim Across America," says Jill DeSimone.
  • "Jill has been supporting Swim Across America for many years," commented Pam Ryan, Swim Across America board chair.
  • Swim Across America was founded in 1987 with its first open water charity swim in Long Island Sound.

Sagard Healthcare Announces Closing of Credit Facility and Recent Investment Highlights

Retrieved on: 
Thursday, January 4, 2024
Biotechnology, Commercial Building & Real Estate, Construction & Property, FDA, Professional Services, Health, Pharmaceutical, Medical Devices, Health Insurance, Asset Management, Finance, US FDA, Professional corporation, Health care, United Therapeutics, Partner, Helicobacter pylori, MannKind Corporation, Therapy, Pulmonary hypertension, Esophagitis, Growth, Investment, Dostarlimab, Orthostatic hypertension

Sagard Healthcare – a biopharmaceutical royalty and credit investor – today announced several developments and milestones for the strategy, including the closing of a $250 million permanent credit facility and the completion of nearly $250 million of new investments.

Key Points: 
  • Sagard Healthcare – a biopharmaceutical royalty and credit investor – today announced several developments and milestones for the strategy, including the closing of a $250 million permanent credit facility and the completion of nearly $250 million of new investments.
  • Sagard Healthcare invests in approved and medically-necessary biopharmaceuticals, medical devices, and diagnostics through royalty monetization, revenue interest financing and secured credit investments.
  • Sagard is pleased to announce that in December 2023, it closed a $250 million revolving credit facility with a syndicate of lenders.
  • The facility is expected to grow in size as Sagard continues to expand its portfolio of royalty and credit investments.

Jemperli (dostarlimab for injection) plus carboplatin and paclitaxel approved in Canada as a treatment option for primary advanced or recurrent dMMR/MSI-H endometrial cancer

Retrieved on: 
Thursday, November 16, 2023
Orbis, Carboplatin, Paclitaxel, Priority review, Woman, Oncology nursing, Health Canada, Annual general meeting, SGO, Policy, Food, Platinum, Gynecologic Oncology (journal), US Foods, ESMO, Patient, Society of Gynecologic Oncology, Part, FDA, GOC, Endometrial cancer, Health, Standard of care, Cancer, CCSN, Survival, Partnership, Oncology, Society, MSI-H, Birth control, Pharmaceutical industry, Dostarlimab, MISSISSAUGA

Jemperli is the only immuno-oncology treatment approved for this patient population in combination with chemotherapy in Canada.

Key Points: 
  • Jemperli is the only immuno-oncology treatment approved for this patient population in combination with chemotherapy in Canada.
  • [1]
    "Today's approval supports our ambition for Jemperli to advance the standard of care for Canadian adult patients with primary advanced or recurrent dMMR/MSI-H endometrial cancer," said Marni Freeman, Country Medical Director at GSK Canada.
  • "This expanded approval of Jemperli offers a new care option to healthcare professionals treating this patient population with high unmet need."
  • "The CCSN is pleased to see a newly approved innovative treatment option for patients in Canada.

She Did it!! Ultra Marathon Swimmer Sarah Thomas Completes Swim Across Lake Mead Swimming 47.5 Miles to Make Waves to Fight Cancer for Swim Across America

Retrieved on: 
Tuesday, October 10, 2023
Johns Hopkins University, SAA, UCSF Benioff Children's Hospital, Multimedia, Golden Gate Bridge, Health care, Memorial Sloan Kettering Cancer Center, Hope, Isle, Swimming, Breast cancer, Dostarlimab, The New England Journal of Medicine, Seattle Cancer Care Alliance, Beauty, North Channel (Great Britain and Ireland), GSK plc, Atlantic Ocean, Swim Across America, UCSF, Weill Cornell Medicine, Hoover Dam, Cancer, Sound, Record, Patient, FDA, Movement, Nantucket Cottage Hospital, Immunotherapy, Clinical trial, Volunteering, English, Research, Children's Hospital Oakland Research Institute, Breast Cancer Awareness Month, Water, Hotel, Dentistry, Quarry, Birth control, Lake Mead, Pembrolizumab

LAS VEGAS, Oct. 10, 2023 /PRNewswire-PRWeb/ -- On October 7, 2023, ultra marathon swimmer Sarah Thomas set another world record with a monumental swim that no other swimmer has ever attempted. Sarah completed a 47.5-mile swim (pending ratification) of the entire length of Lake Mead – from the Colorado River to the Hoover Dam. The swim took her 26 hours, 45 minutes and 45 seconds (26:45:45) to complete. Sarah, a breast cancer survivor, took on this swim not just to break another world record, but to help make waves in the fight against cancer and to raise critical funds for cancer research with Swim Across America.

Key Points: 
  • Sarah completed a 47.5-mile swim (pending ratification) of the entire length of Lake Mead – from the Colorado River to the Hoover Dam.
  • I'm a cold water swimmer, so this was a bit warmer than I'm used to, but it ended up being lovely," said Sarah Thomas.
  • I'm so excited to be able to accomplish swimming in Lake Mead, and as a breast cancer survivor, to do it during Breast Cancer Awareness Month, all while raising crucial funds for cancer research with Swim Across America."
  • Sarah has supported Swim Across America since 2018, when the inaugural Swim Across America - Denver swim was held in her home community.

Promega to Develop Microsatellite Instability (MSI) Companion Diagnostic IVD Kit in Collaboration With GSK

Retrieved on: 
Tuesday, October 3, 2023
Stem Cells, Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, Neoplasm, GSK, DNA, Therapy, ICI, Marketing, Microsatellite instability, Cancer, Biomarker, Promega, Corporation, Patient, MSI, Medicine, Mab, IVD, MSI-H, CDX, FDA, NMPA, PCR, ChromeOS, Pharmaceutical industry, EU, Dostarlimab

Promega Corporation today announced it plans to develop and commercialize a microsatellite instability (MSI) companion diagnostic (CDx) IVD kit with GSK to identify adult cancer patients with MSI-H solid tumors who may be eligible for potential treatment with GSK’s Jemperli (dostarlimab-gxly).

Key Points: 
  • Promega Corporation today announced it plans to develop and commercialize a microsatellite instability (MSI) companion diagnostic (CDx) IVD kit with GSK to identify adult cancer patients with MSI-H solid tumors who may be eligible for potential treatment with GSK’s Jemperli (dostarlimab-gxly).
  • The collaboration agreement leverages the companies’ complementary strengths to expand personalized healthcare options to more patients using high quality diagnostic tools and treatments.
  • “This collaboration underscores our commitment to enabling patient access to targeted therapies,” says Alok Sharma, Global Clinical Market Director at Promega.
  • Promega has received innovation status and priority review by the NMPA in China and also intends to seek regulatory clearance for a Promega MSI IVD in China.

Ultra Marathon Swimmer Sarah Thomas Will Attempt 50-Mile Swim in Lake Mead from Colorado River to the Hoover Dam and Make Waves to Fight Cancer with Swim Across America

Retrieved on: 
Thursday, September 28, 2023
Golden Gate Bridge, Dostarlimab, Volunteering, GSK plc, English, Sound, North Channel (Great Britain and Ireland), Health care, The New England Journal of Medicine, Johns Hopkins University, Clinical trial, Seattle Cancer Care Alliance, Cancer, SAA, Record, Hope, UCSF Benioff Children's Hospital, Research, Multimedia, Immunotherapy, Movement, Beauty, Patient, UCSF, Nantucket Cottage Hospital, Water, Atlantic Ocean, Memorial Sloan Kettering Cancer Center, Isle, Swim Across America, Hoover Dam, Weill Cornell Medicine, FDA, Children's Hospital Oakland Research Institute, Breast cancer, Hotel, Dentistry, Birth control, Dam, Pharmaceutical industry, Lake Mead, Pembrolizumab

LAS VEGAS, Sept. 28, 2023 /PRNewswire-PRWeb/ -- On October 6, 2023, ultra marathon swimmer Sarah Thomas will attempt to set another world record with a monumental swim that no other swimmer has ever attempted. Sarah will set out to complete a 50-mile swim of the entire length of Lake Mead – from the Colorado River to the Hoover Dam. She estimates the swim will take her 30 hours to complete. Sarah, a breast cancer survivor, is undertaking this swim not just to break another world record, but to help make waves in the fight against cancer and to raise critical funds for cancer research with Swim Across America.

Key Points: 
  • Sarah will set out to complete a 50-mile swim of the entire length of Lake Mead – from the Colorado River to the Hoover Dam.
  • Sarah already holds a long list of record-breaking feats and hopes to add the Lake Mead swim to her list.
  • "After my first visit to the Hoover Dam in February 2021, I knew I had to swim across Lake Mead," said Sarah.
  • Sarah's swim across Lake Mead will start in South Cove, where her favorite river, The Colorado, enters the lake.

Swim Across America Launches College Cup and College Ambassador Programs

Retrieved on: 
Tuesday, September 26, 2023
Golden Gate Bridge, Dostarlimab, Johns Hopkins University, Patient, Nantucket Cottage Hospital, Weill Cornell Medicine, Northeastern University, Environment, GSK plc, College Cup, University, Face, Seattle Cancer Care Alliance, UCSF Benioff Children's Hospital, Research, Vasa, North Star College Cup, Athlete, Swimming, UCSF, FDA, Health care, Cancer, SAA, Providence College, Immunotherapy, Outline, Water, Memorial Sloan Kettering Cancer Center, Children's Hospital Oakland Research Institute, The New England Journal of Medicine, Partnership, College, Roger Williams University, Student, Sound, Clinical trial, University of South Florida, Movement, Nursing, Hotel, Swim Across America, Pembrolizumab

CHARLOTTE, N.C., Sept. 26, 2023 /PRNewswire-PRWeb/ -- Swim Across America (SAA) is pleased to announce two new programs aimed at college students and college swim teams who want to make a bigger impact in their community through leadership, fundraising, and friendly competition. The Swim Across America College Cup features 30+ collegiate, club and alumni teams and more than 1,000 participants all united to make waves in the fight against cancer through swimming. The second program is the SAA College Ambassador program where 21 college swimmers and ambassadors have been selected to represent Swim Across America throughout the school year to help raise awareness on the importance of making waves to fight cancer. Both programs are supported through partnerships with College Swimming Coaches Association of America (CSCAA) and Vasa, the fitness training company for swimmers.

Key Points: 
  • New Programs Offer Fun, Fresh, and Exciting Ways for College Students to Make a Bigger Impact With Swim Across America, College Swimming Coaches Association of America, Inc. and Vasa are proud partners of College Cup Competition
    CHARLOTTE, N.C., Sept. 26, 2023 /PRNewswire-PRWeb/ -- Swim Across America (SAA) is pleased to announce two new programs aimed at college students and college swim teams who want to make a bigger impact in their community through leadership, fundraising, and friendly competition.
  • Through December 1, 2023, college or college-affiliated swim teams will compete in the Swim Across America College Cup , a fundraising competition among collegiate teams in the U.S.
  • Swim Across America is also excited to announce another new college initiative, the Swim Across America College Ambassadors program.
  • Earlier this year, Swim Across America invited college students to apply for the Swim Across America College Ambassadors program.

AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 7, 2023
SAB, GSK, RA, Therapy, Roche, Infection, Coronavirus Scientific Advisory Board, Saṃsāra, Immunology, G&A, Atopic dermatitis, R, BTLA, IGA, Endometrial cancer, Federation, Translational medicine, Flagship Pioneering, Acquisition, Patient, Investment, SAN, MSI-H, GPP, PD-1, Federation of Clinical Immunology Societies, Collaboration, AD, Research, Autoimmunity, Rheumatoid arthritis, Pharmaceutical industry, Cryptocurrency, Inflammation, Dostarlimab, Sanofi

Initiating a global Phase 2b trial for rosnilimab, a PD-1 agonist antibody, in rheumatoid arthritis (RA) later in Q3 2023 and a second Phase 2 trial, in an indication yet to be announced, by year-end 2023

Key Points: 
  • Initiating a global Phase 2b trial for rosnilimab, a PD-1 agonist antibody, in rheumatoid arthritis (RA) later in Q3 2023 and a second Phase 2 trial, in an indication yet to be announced, by year-end 2023
    SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the second quarter ended June 30, 2023 and provided a business update.
  • She had extensive experience at Bristol-Meyers Squibb where she led teams that advanced more than 20 compounds into clinical development.
  • Among her prior roles includes serving as Principia’s chief medical officer from 2018 until the Sanofi acquisition in September 2020.
  • Cash, cash equivalents and investments totaled $488.7 million as of June 30, 2023, compared to $584.2 million as of December 31, 2022, for a decrease of $95.5 million.

Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Retrieved on: 
Monday, July 31, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Orbis, GSK, Priority review, US Foods, Risk, Prescription Drug User Fee Act, Radiation, Society, SGO, Senior, Diarrhea, Society of Gynecologic Oncology, The New England Journal of Medicine, ESMO, European Medicines Agency, Clinical trial, Paclitaxel, Hope, Gynecologic Oncology (journal), Part, Carboplatin, Hypothyroidism, European Society for Medical Oncology, PFS, Rash, Hypertension, GSK plc, Endometrial cancer, HIV disease progression rates, MD, Patient, Division, FORCE, Annual general meeting, Washington University School of Medicine, United Kingdom, European Society of Gynaecological Oncology, ITT, Death, III, News, Food, Safety, Pharmaceutical industry, Dostarlimab

Hesham Abdullah, Senior Vice President, Global Head of Oncology Development, GSK, said: “Today’s expanded approval of Jemperli redefines the treatment landscape for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Key Points: 
  • Hesham Abdullah, Senior Vice President, Global Head of Oncology Development, GSK, said: “Today’s expanded approval of Jemperli redefines the treatment landscape for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
  • Until now, chemotherapy alone has been the standard of care with many patients experiencing disease progression.
  • These results and today’s approval underscore our belief in the potential for Jemperli to transform cancer treatment as a backbone immuno-oncology therapy.”
    With this approval, Jemperli is now indicated earlier in treatment in combination with chemotherapy for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
  • The most common treatment-emergent adverse events (≥ 20%) in patients receiving Jemperli plus chemotherapy were rash, diarrhea, hypothyroidism and hypertension.

New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

Retrieved on: 
Thursday, June 8, 2023
PDAC, TNBC, Communication, Chronic lymphocytic leukemia, Precigen, Doctor of Philosophy, Investigational New Drug, GILD, MD, Patient, NYSE, News, Bone marrow, CLL, University, Oncolytics Biotech, Acute lymphoblastic leukemia, DLBCL, NK, Research, MD Anderson Cancer Center, B-cell lymphoma, Gilead, GSK plc, ONC, TSX, PD-1, FDA, Pancreatic cancer, GSK, Gilead Sciences, Trinket, Pela, ALL, Cancer, ACT Biotech Inc, National Cancer Institute, Standard of care, Therapy, ORR, Inflammation, Pelareorep, Triple-negative breast cancer, Cell death, Paclitaxel, Dostarlimab, Mantle cell lymphoma, MCL, FTD, Breast cancer, Pharmaceutical industry, Medical imaging, Cryptocurrency, EU, Dragonfly, Agency

VANCOUVER, British Columbia, June 8, 2023 /PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer. A study put out by researchers at the University of Texas MD Anderson Cancer Center recently detailed a previously unexplained type of cell death that could open the door for novel cancer therapies. How we arm ourselves in the battle against cancer is rapidly changing, thanks to novel mechanisms giving important results, such as those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Gilead Sciences, Inc. (NASDAQ: GILD), iTeos Therapeutics, Inc. (NASDAQ: ITOS), GSK plc (NYSE: GSK), and Precigen, Inc. (NASDAQ: PGEN).

Key Points: 
  • VANCOUVER, British Columbia, June 8, 2023 /PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer.
  • A study put out by researchers at the University of Texas MD Anderson Cancer Center recently detailed a previously unexplained type of cell death that could open the door for novel cancer therapies.
  • At this year's Future of Oncology Virtual Symposium in early April, Oncolytics was selected to participate in a panel presentation called Novel Mechanisms with Important Readouts.
  • Pelareorep's impacts on cancer are also being researched, including through Oncolytics' first and longest-standing focus on its HR-positive HER2-negative metastatic breast cancer program.